rence or endoscopic recurrence. Postoperative endoscopic recurrence (PER), which is usually quantified using a Rutgeerts scoring system, 5 typically precedes clinical recurrence and PER was reported to occur in almost 58% of CD patients within 1 year of intestinal resection. 6 In this issue, Lee et al.
EDITORIAL
Crohn's disease (CD) is a chronic inflammatory disease that affects the entire gastrointestinal tract. Complications caused by CD, including strictures, perforations, and fistulas, often lead patients to undergo surgery, including intestinal resection. Several studies have reported that 50−80% of CD patients undergo the surgery during their lifetime. 1 In Korea,
Ye et al. reported that the cumulative probability of intestinal resection at 1, 5, and 10−15 years after a diagnosis of CD was 15.5%, 25.0%, and 32.8%, respectively. 2 In a more extensive study by Park et al., the cumulative probability of intestinal resection at 10, 20, and 30 years after a diagnosis of CD was 43.5%, 70.0%, and 76.1%, respectively. 3 These data suggest that the intestinal resection rate of Korean CD patients is not lower than that of Western patients and that Korean CD patients may, in fact, have a similar clinical course to Western CD patients. However, intestinal resection does not cure CD, and many patients suffer from postoperative recurrences of the disease. The recurrence of disease necessitates repeated intestinal resection, with up to 50% of patients undergoing additional surgery after 20 years. 4 Recent studies have also focused on the effectiveness of tumor necrosis factor (TNF)-α antagonists in treating and preventing PER, especially in high-risk patients. TNF-α antagonist therapy (including infliximab and adalimumab) seemed more effective than AZT in preventing and treating PER in many studies. 9, 10 Despite these studies being performed with few patients and without long-term follow-up, and although safety and cost issues should also be considered, the use of TNF-α antagonists is currently recommended as appropriate treatment in the high-risk patient group. In Korea, the efficacy of TNF-α antagonists in preventing the postoperative recurrence of CD has not yet been reported. Therefore, prospective large-scale studies are needed to clarify the burden of postoperative recurrence of CD and to determine the high-risk factors of recurrence in Korean CD patients. Furthermore, the efficacy of TNF-α antagonists in improving the long-term prognosis and quality of life of highrisk patients should be further investigated.
